As a solid oral dosage form, the combined afoxolaner and milbemycin oxime chewable tablet is the most extensively documented downstream configuration for veterinary API. The authorized commercial presentations use a fixed weight ratio of 5:1 afoxolaner to milbemycin oxime, delivering 2.5 mg/kg and 0.5 mg/kg body weight respectively. In practice, this is translated into discrete tablet strengths for five body weight bands. The chewable matrix is not a conventional immediate-release tablet; it contains humectants such as glycerin and propylene glycol, palatability components including poultry liver powder, and low-moisture plasticizer systems that permit deformable, extruded or compressed chewable masses. Finished tablets are typically scored, oval or rectangular, and packaged in aluminium/aluminium or PVC/PVDC blisters with desiccant. During production, the granulation or dough temperature is maintained below 40°C to limit thermo-oxidative degradation of the macrocyclic lactone. Content uniformity is measured per USP ⁄905⁄ or Ph. Eur. 2.9.40. Release testing includes HPLC assay for both actives, dissolution by USP ⁄711⁄, water determination by USP ⁄921⁄, and loss on drying by USP ⁄731⁄. Because milbemycin oxime is moisture- and light-sensitive, forced degradation and photostability programmes under ICH Q1A(R2) and VICH GL5 are applied to justify packaging and storage limits.

Scale-up bottlenecks in chewable tablet manufacture are most often observed in high-shear mixers and low-shear extruders. In high-shear mixing, lipid-based binders can migrate toward the granule surface when bowl temperature rises, producing batch-to-batch variance in hardness and dissolution. Jacketed bowls and intermittent cooling are used to keep product temperature below 35°C. On production-scale twin-screw or single-screw extruders, back-pressure increases when the dough moisture falls below the validated range; this can fracture API crystals and shift particle size distribution. Therefore, in-process controls include moisture at the extruder inlet and hardness testing of the cut tablets. Blister lines require relative humidity below 30% and light-protective amber or opaque films to prevent photodegradation of milbemycin oxime. Commercial reference presentations are summarized below.

What Changes When the Active Pair Moves From Chewable Solids to Aqueous Injectable Vehicles?

In preformulation screening, the pair presents different constraints than in chewable solids. Afoxolaner exhibits negligible aqueous solubility and high lipophilicity characteristic of isoxazolines; milbemycin oxime, as a macrocyclic lactone, is lipophilic and prone to acid-catalysed hydrolysis at low pH. Injectable formulations therefore require either non-aqueous solution vehicles or aqueous suspension systems. For solution development, solvent systems containing dimethylacetamide, benzyl alcohol, or glycerol formal are screened; each solvent must be justified against ICH Q3C or VICH GL18 residual solvent limits. Aqueous suspension candidates employ wet milling with polysorbate 80 or poloxamer 188 as wetting agents, and particle size distribution is controlled by laser diffraction. Terminal sterilization using moist heat at 121°C for 15 minutes must be evaluated for degradation of milbemycin oxime; where degradation exceeds specification limits, aseptic processing under ISO 5 conditions is required, with sterility testing per USP ⁄71⁄ and bacterial endotoxin testing per USP ⁄85⁄. Container-closure integrity is verified per USP ⁄1207⁄. Published data for this specific combination in injectable form is limited, so formulation-specific forced degradation under ICH Q1A(R2) and in vivo bioavailability data are required before any dosing claim can be made.

When Low-Dose Capsule Blending Requires Geometric Dilution Validation

Because the milbemycin oxime fraction per capsule can be as low as 1.875 mg, low-dose capsule filling demands geometric dilution rather than simple bin blending. Direct blending of the two APIs with microcrystalline cellulose PH-102, lactose monohydrate, and croscarmellose sodium requires pre-sieving through a 250 µm mesh to break agglomerates and prevent segregation-induced content variability. A V-blender or bin blender is charged in stages, starting with a premix of milbemycin oxime and a portion of filler at low shear for 10–15 minutes; the premix is then combined with afoxolaner and remaining excipients. Blend uniformity samples are drawn from at least 10 locations and assayed by HPLC, with acceptance criteria referenced to USP ⁄905⁄. Where the angle of repose exceeds 40°, dry granulation or low-shear wet granulation is introduced to improve flow for high-speed capsule filling. Final hard gelatin capsules are filled to target weight with fill weight variation controlled by automated checkweighing; disintegration is tested per USP ⁄701⁄, and moisture is limited to prevent capsule shell brittleness or API hydrolysis. Avoid combination with amine-based excipients unless compatibility studies rule out acid-base interaction with the macrocyclic lactone ring.

Powder and granule intermediates of the combined API are produced either as compaction-ready granules for subsequent tablet compression or as reconstitutable oral powders for sachet packaging. During fluid-bed granulation, the powder blend is sprayed with a binder solution containing povidone K-30 or hypromellose; inlet air temperature is held at 45°C to 55°C, while product temperature is maintained below 40°C to protect milbemycin oxime. Moisture control is critical: loss on drying by USP ⁄731⁄ is typically specified at ≤2.0% for reconstitutable granules, and water activity is monitored to prevent hydrolytic degradation. Granule particle size is measured by sieve analysis, with oversize fractions milled through a 0.8 mm screen. Because milbemycin oxime is photolabile, bulk powder and granule handling must occur in amber glass or opaque HDPE containers, and packaging is qualified under ICH Q1B and VICH GL5. Sachet presentation requires a desiccant pouch and low-moisture barrier laminate. Process yields are most affected by granule segregation during discharge; single-pot processing or vacuum transfer reduces loss of fines and preserves content uniformity.

Premix Dilution and Feed-Suspension Compatibility Boundaries

In premix operations, the carrier substrate must be matched to the particle size distribution and bulk density of the API blend. Ground corn, lactose monohydrate, or silica-based carriers are used for Type B or Type C medicated feed premises, as defined in 21 CFR 558.3. Homogeneity is tested by sampling at least 10 random points, with HPLC assay acceptance criteria based on the intended dilution ratio. Segregation risk arises when the difference in bulk density between carrier and active premix exceeds 0.2 g/cm³; this is controlled by reducing carrier particle size or by adding a mineral oil dust suppressant at ≤1.0%. However, published regulatory authorization for afoxolaner and milbemycin oxime combination premixes intended for food-producing animals is limited, and any such application would require residue depletion studies and withdrawal period establishment under FDA 21 CFR Part 500 or equivalent regional requirements. For companion animal only, premix-style top-dress powders may be prepared without feed-mill registration, but GMP standards under 21 CFR 210/211 still apply to the manufacturing site and analytical release.

Oral Solution Vehicle Selection and Preservative Efficacy Requirements

Liquid oral dosing of afoxolaner and milbemycin oxime requires a vehicle system that maintains both actives in solution or homogenous suspension throughout the labelled in-use period. Non-aqueous oral solutions are prepared using co-solvents such as ethanol, propylene glycol, and glycerol, with or without buffered aqueous components. Because milbemycin oxime degrades under strongly acidic conditions, solution pH is normally adjusted to 4.0–6.0 with citrate or phosphate buffer, and pH is verified by USP ⁄791⁄. Preservatives such as methylparaben and propylparaben are included for multidose bottles, and antimicrobial effectiveness is tested per Ph. Eur. 5.1.3 or USP ⁄51⁄. The finished product is filled into amber Type III glass or HDPE bottles equipped with a calibrated dosing syringe or dropper; dose accuracy is evaluated at the minimum and maximum labelled volumes. Nitrogen headspace sparging is used to limit oxidative degradation of the macrocyclic lactone. Published data for oral solution formulations of this specific combination is limited, so forced degradation under ICH Q1A(R2) and photostability under ICH Q1B must be generated before a stability claim can be assigned.